Grigoriadis Dimitri E
Department of Pharmacology and Lead Discovery, Neurocrine Biosciences, Inc., 12790 El Camino Real, San Diego, CA 92130, USA.
Expert Opin Ther Targets. 2005 Aug;9(4):651-84. doi: 10.1517/14728222.9.4.651.
The treatment of mood disorders has been the subject of intense study for more than half a century and has resulted in the discovery and availability of a number of compounds that have seen tremendous success in the management of major depression and anxiety-related disorders. In spite of this success, these drugs have not provided a complete therapeutic solution for all patients and this has revitalised the need for a greater understanding of the underlying molecular mechanisms and targets involved in these disorders. Elucidation of these novel targets will enable the development of a better class of compounds which could benefit a greater majority of the patient population and be devoid of the current side effect liabilities. Towards that end, this review examines, in detail, the prospect of one such target, the corticotropin-releasing factor system, as having an enhanced therapeutic profile with the potential of a broader range of efficacy with reduced side effect liabilities.
半个多世纪以来，情绪障碍的治疗一直是深入研究的主题，并促成了多种化合物的发现与应用，这些化合物在重度抑郁症及焦虑相关障碍的治疗中取得了巨大成功。尽管取得了这样的成功，但这些药物并未为所有患者提供完整的治疗方案，这重新激发了人们深入了解这些疾病潜在分子机制和靶点的需求。阐明这些新靶点将有助于开发出一类更好的化合物，使更多患者受益，且不存在当前药物的副作用问题。为此，本综述详细探讨了一个这样的靶点——促肾上腺皮质激素释放因子系统，其具有增强的治疗特性，有可能在疗效范围更广的同时降低副作用。
